期刊
AGING CELL
卷 19, 期 1, 页码 -出版社
WILEY
DOI: 10.1111/acel.13054
关键词
Alzheimer's disease; amyloid-beta; APP processing; cAMP; PKA pathway; photobiomodulation therapy; SIRT1
资金
- Natural Science Foundation of Guangdong Province [2014A030313419]
- National Natural Science Foundation of China [31470072, 61361160414]
A hallmark of Alzheimer's disease (AD) is the accumulation of amyloid-beta (A beta), which correlates significantly with progressive cognitive deficits. Although photobiomodulation therapy (PBMT), as a novel noninvasive physiotherapy strategy, has been proposed to improve neuronal survival, decrease neuron loss, ameliorate dendritic atrophy, and provide overall AD improvement, it remains unknown whether and how this neuroprotective process affects A beta levels. Here, we report that PBMT reduced A beta production and plaque formation by shifting amyloid precursor protein (APP) processing toward the nonamyloidogenic pathway, thereby improving memory and cognitive ability in a mouse model of AD. More importantly, a pivotal protein, SIRT1, was involved in this process by specifically up-regulating ADAM10 and down-regulating BACE1, which is dependent on the cAMP/PKA pathway in APP/PS1 primary neurons and SH-SY5Y cells stably expressing human APP Swedish mutation (APPswe). We further found that the activity of the mitochondrial photoacceptor cytochrome c oxidase (CcO) was responsible for PBMT-induced activation of PKA and SIRT1. Together, our research suggests that PBMT as a viable therapeutic strategy has great potential value in improving cognitive ability and combatting AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据